77 related articles for article (PubMed ID: 10540537)
1. The effects of glibenclamide on serum lipids and lipoproteins in type II non-insulin dependent diabetes mellitus.
Mughal MA; Maheri WM; Aamir K; Jan M; Ali M
J Pak Med Assoc; 1999 Apr; 49(4):89-92. PubMed ID: 10540537
[TBL] [Abstract][Full Text] [Related]
2. Effect of acarbose on glycemic control, serum lipids and lipoproteins in type 2 diabetes.
Mughal MA; Memon MY; Zardari MK; Tanwani RK; Ali M
J Pak Med Assoc; 2000 May; 50(5):152-6. PubMed ID: 11242714
[TBL] [Abstract][Full Text] [Related]
3. The effects of oral hypoglycaemic drugs on serum lipids and lipoproteins in non-insulin-dependent diabetes (NIDDM).
Elkeles RS
Diabete Metab; 1991 May; 17(1 Pt 2):197-200. PubMed ID: 1936476
[TBL] [Abstract][Full Text] [Related]
4. Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes.
Vakkilainen J; Mero N; Schweizer A; Foley JE; Taskinen MR
Diabetes Metab Res Rev; 2002; 18(6):484-90. PubMed ID: 12469362
[TBL] [Abstract][Full Text] [Related]
5. Sustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetes.
Tan MH; Johns D; Strand J; Halse J; Madsbad S; Eriksson JW; Clausen J; Konkoy CS; Herz M;
Diabet Med; 2004 Aug; 21(8):859-66. PubMed ID: 15270789
[TBL] [Abstract][Full Text] [Related]
6. The effect of metformin on glycemic control, serum lipids and lipoproteins in diet alone and sulfonylurea-treated type 2 diabetic patients with sub-optimal metabolic control.
Mughal MA; Jan M; Maheri WM; Memon MY; Ali M
J Pak Med Assoc; 2000 Nov; 50(11):381-6. PubMed ID: 11126815
[TBL] [Abstract][Full Text] [Related]
7. Glibenclamide improves postprandial hypertriglyceridaemia in type 2 diabetic patients by reducing chylomicrons but not the very low-density lipoprotein subfraction levels.
Skrapari I; Perrea D; Ioannidis I; Karabina SA; Elisaf M; Tselepis AD; Karagiannacos P; Katsilambros N
Diabet Med; 2001 Oct; 18(10):781-5. PubMed ID: 11678967
[TBL] [Abstract][Full Text] [Related]
8. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
Comaschi M; Corsi A; Di Pietro C; Bellatreccia A; Mariz S;
Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):373-9. PubMed ID: 17919894
[TBL] [Abstract][Full Text] [Related]
9. Effects of glibenclamide on serum lipids, lipoproteins, thromboxane, beta-thromboglobulin, and prostacyclin in non-insulin-dependent diabetes mellitus.
Waysbort J; Regitz G; Chaimowitz D; Tuval M; Nakash I; Brunner D
Clin Ther; 1988; 10(4):358-71. PubMed ID: 2978874
[TBL] [Abstract][Full Text] [Related]
10. Insulin and sulfonylurea therapy in NIDDM patients. Are the effects on lipoprotein metabolism different even with similar blood glucose control?
Romano G; Patti L; Innelli F; Di Marino L; Annuzzi G; Iavicoli M; Coronel GA; Riccardi G; Rivellese AA
Diabetes; 1997 Oct; 46(10):1601-6. PubMed ID: 9313756
[TBL] [Abstract][Full Text] [Related]
11. Pioglitazone compared to glibenclamide on lipid profile and inflammation markers in type 2 diabetic patients during an oral fat load.
Derosa G; Cicero AF; Fogari E; D'Angelo A; Bianchi L; Maffioli P
Horm Metab Res; 2011 Jun; 43(7):505-12. PubMed ID: 21590648
[TBL] [Abstract][Full Text] [Related]
12. Effect of insulin and sulfonylurea therapy, at the same level of blood glucose control, on low density lipoprotein subfractions in type 2 diabetic patients.
Rivellese AA; Patti L; Romano G; Innelli F; Di Marino L; Annuzzi G; Iavicoli M; Coronel GA; Riccardi G
J Clin Endocrinol Metab; 2000 Nov; 85(11):4188-92. PubMed ID: 11095452
[TBL] [Abstract][Full Text] [Related]
13. Meal-induced platelet activation in Type 2 diabetes mellitus: effects of treatment with repaglinide and glibenclamide.
Yngen M; Ostenson CG; Hjemdahl P; Wallén NH
Diabet Med; 2006 Feb; 23(2):134-40. PubMed ID: 16433710
[TBL] [Abstract][Full Text] [Related]
14. Effect of glibenclamide in insulin-treated diabetic patients with a residual insulin secretion.
Mauerhoff T; Ketelslegers JM; Lambert AE
Diabete Metab; 1986 Feb; 12(1):34-8. PubMed ID: 3084315
[TBL] [Abstract][Full Text] [Related]
15. Combination insulin/glyburide therapy in type II diabetes mellitus. Effects on lipoprotein metabolism and glucoregulation.
Falko JM; Osei K
Am J Med; 1985 Sep; 79(3B):92-101. PubMed ID: 3931467
[TBL] [Abstract][Full Text] [Related]
16. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus.
Schwartz EA; Koska J; Mullin MP; Syoufi I; Schwenke DC; Reaven PD
Atherosclerosis; 2010 Sep; 212(1):217-22. PubMed ID: 20557887
[TBL] [Abstract][Full Text] [Related]
17. The effects of glibenclamide and insulin on plasma high density lipoprotein in diabetics.
Tamai T; Nakai T; Yamada S; Kobayashi T; Hayashi T; Kutsumi Y; Oida K; Takeda R
Artery; 1981; 9(6):477-93. PubMed ID: 6802107
[TBL] [Abstract][Full Text] [Related]
18. The effect of glibenclamide and metformin on serum lipoproteins in type 2 diabetes.
Rains SG; Wilson GA; Richmond W; Elkeles RS
Diabet Med; 1988 Oct; 5(7):653-8. PubMed ID: 2975549
[TBL] [Abstract][Full Text] [Related]
19. The effect of sulphonylurea therapy on serum total cholesterol and high density lipoprotein cholesterol.
Singh T; Singh S; Bhullar GS
J Indian Med Assoc; 1992 Oct; 90(10):259-61. PubMed ID: 1287082
[TBL] [Abstract][Full Text] [Related]
20. Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors.
Ceriello A; Del Prato S; Bue-Valleskey J; Beattie S; Gates J; de la Peña A; Malone J
J Diabetes Complications; 2007; 21(1):20-7. PubMed ID: 17189870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
